206 related articles for article (PubMed ID: 16670205)
21. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S; Middleton MR; O'Byrne KJ; Clemons M; Ranson M; Hassan J; Anderson H; Burt PA; Fairve-Finn C; Stout R; Dowd I; Ashcroft L; Beresford C; Thatcher N
Cancer; 2003 Aug; 98(3):542-53. PubMed ID: 12879472
[TBL] [Abstract][Full Text] [Related]
23. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Lecomte J; Berghmans T; Thiriaux J; Florin MC; Efremidis A; Alexopoulos CG; Recloux P; Ninane V; Mommen P; Paesmans M; Klastersky J;
Ann Oncol; 2002 Jun; 13(6):874-82. PubMed ID: 12123332
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Pereira JR; Fein L; Del Giglio A; Blajman CR; Richardet E; Schwartsmann G; Orlando M; Hall BJ; West TM; van Kooten M
Lung Cancer; 2007 Oct; 58(1):80-7. PubMed ID: 17588704
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Yamamoto N; Nakagawa K; Uejima H; Sugiura T; Takada Y; Negoro S; Matsui K; Kashii T; Takada M; Nakanishi Y; Kato T; Fukuoka M;
Cancer; 2006 Aug; 107(3):599-605. PubMed ID: 16804877
[TBL] [Abstract][Full Text] [Related]
26. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
[TBL] [Abstract][Full Text] [Related]
27. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Bajetta E; Stani SC; De Candis D; Zaffaroni N; Zilembo N; Cortinovis D; Aglione S; Mariani L; Formisano B; Bidoli P
Ann Oncol; 2003 Feb; 14(2):242-7. PubMed ID: 12562651
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Tomizawa Y; Ishihara S; Iijima H; Imai H; Sato K; Yatomi M; Iwasaki Y; Yamada H; Kobayashi G; Ishida E; Inoue T; Aoki H; Watanabe S; Kawashima O; Mori M; Saito R
Am J Clin Oncol; 2007 Oct; 30(5):498-502. PubMed ID: 17921710
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.
Yoshimura M; Imamura F; Ueno K; Uchida J
Clin Lung Cancer; 2006 Nov; 8(3):208-13. PubMed ID: 17239297
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
Grigorescu AC; Draghici IN; Nitipir C; Gutulescu N; Corlan E
Lung Cancer; 2002 Jul; 37(1):9-14. PubMed ID: 12057861
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
Obasaju CK; Ye Z; Bloss LP; Monberg MJ; Curiel RE
Clin Lung Cancer; 2005 Nov; 7(3):202-7. PubMed ID: 16354316
[TBL] [Abstract][Full Text] [Related]
32. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
[TBL] [Abstract][Full Text] [Related]
34. Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Wang LR; Liu J; Huang MZ; Xu N
J Zhejiang Univ Sci B; 2007 May; 8(5):307-13. PubMed ID: 17542057
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Maestu I; Gómez-Aldaraví L; Torregrosa MD; Camps C; Llorca C; Bosch C; Gómez J; Giner V; Oltra A; Albert A
Lung Cancer; 2003 Dec; 42(3):345-54. PubMed ID: 14644523
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
Sederholm C; Hillerdal G; Lamberg K; Kölbeck K; Dufmats M; Westberg R; Gawande SR
J Clin Oncol; 2005 Nov; 23(33):8380-8. PubMed ID: 16293868
[TBL] [Abstract][Full Text] [Related]
37. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Alvarez RD; Mannel R; García AA; Gallion HH; Lucci J; Kilgore LC; Numnum TM; Zou SX; Orlando M; Tai DF
Gynecol Oncol; 2009 Dec; 115(3):389-95. PubMed ID: 19800673
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
39. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Hasegawa Y; Miura D; Kitamura C; Suzuki T; Kobayashi K; Sato N
Chemotherapy; 2013; 59(5):346-53. PubMed ID: 24821009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
